Replies to post #330493 on Avid Bioservices Inc (CDMO)

[biopharm]

when Bavi failed.

Interesting, because Bavi / PS Targeting never failed. The trial failed because as we know anyone can design a trial to fail and have it stopped for any number of reasons

When Docetaxel control arm wants to fail it can fail to bring on an FDA approval that is friendly to some BPs but for Bavituximab/PS Targeting? That is another story

Now if Bavituximab/PS Targeting was truly a failure, then Robert Garnick would not have landed at Peregrine and Jeanette Bleecker in Fargo ND working for ex BMS, CEO to Clinical Supplies Management = Gerald Finken, would not have been needed to be paid, sabotage trials etc

Biomarkers are indeed cool though now, especially since the protein pathways and targets have all been exposed, due to PS Targeting

Cotara+Bavituximab ...now that would really disrupt the Merckly families within Big Pharma and remember the FDA already has a phase III design approved and ready for launch

Now back to watching how some other MOAs hype about reducing MDSCs when the one patent that does reduce MDSCs is PS Targeting

My bet is on not all BPs playing well in the sandbox